Featured Research

from universities, journals, and other organizations

PSA Predicts Treatment Success In Advanced Prostate Cancer

Date:
August 24, 2006
Source:
University of Michigan Health System
Summary:
A test used to detect prostate cancer can also help doctors know when treatment is working. A man's prostate specific antigen, or PSA, level after seven months of hormone therapy for advanced prostate cancer predicted how long he would survive, according to a new multicenter study.

A test used to detect prostate cancer can also help doctors know when treatment is working. A man's prostate specific antigen, or PSA, level after seven months of hormone therapy for advanced prostate cancer predicted how long he would survive, according to a new multicenter study conducted by the Southwest Oncology Group and led by researchers at the University of Michigan Comprehensive Cancer Center.

The study evaluated 1,345 men with prostate cancer that had spread to distant parts of the body. The men were treated with seven months of androgen deprivation therapy, a treatment designed to block the effects of hormones on the cancer. PSA levels were monitored throughout the treatment. The researchers found that men whose PSA dropped below 4.0 ng/ml had a quarter the risk of dying compared to those whose PSA was more than 4.0.

Results of the study appear in the Aug. 20 issue of the Journal of Clinical Oncology.

"Our analysis showed that a low or undetectable PSA after seven months of androgen deprivation therapy is a powerful predictor of risk of death in patients with new metastatic prostate cancer. This could allow oncologists to identify patients who are unlikely to do well with this treatment long before they develop clinical signs of treatment resistance," says lead study author Maha Hussain, M.D., professor of internal medicine at the U-M Medical School.

The researchers found 69 percent of the men maintained a PSA level of less than 4.0 ng/ml after seven months of treatment and 43 percent had an undetectable level of PSA at that time. Patients whose PSA was higher than 4.0 at the end of seven months survived 13 months, while patients whose PSA dropped below 4.0 but above 0.2 lived 44 months and those whose PSA was undetectable, below 0.2 ng/ml, lived 75 months.

The men in the study were enrolled in a Phase III SWOG trial in which they would receive additional treatment after the seven months of initial hormone therapy. That study seeks to accrue 1,512 men. The patient's PSA level before beginning treatment must be at least 5.0 ng/ml to qualify for the study.

A PSA test measures the level in the blood of prostate specific antigen, an enzyme produced by the prostate gland. It is generally used as an initial screening test to detect prostate cancer.

"What is attractive about using PSA to predict survival in metastatic prostate cancer is that it is an easily measurable factor. These findings could help patients avoid ineffective treatment and could help researchers design further trials," Hussain says.

Some 234,460 men will be diagnosed with prostate cancer this year, and 27,350 will die from it, according to the American Cancer Society. For more information about prostate cancer, call U-M's Cancer AnswerLine at 800-865-1125 or go to www.cancer.med.umich.edu/cancertreat/urologiconcology/prostate_cancer.shtml.

In addition to Hussain, study authors were Catherine Tangen, Southwest Oncology Group; Celestia Higano, Puget Sound Oncology Consortium in Seattle; Paul Schelhammer, Devine-Tidewater Urology in Norfolk, Va.; James Faulkner, Southwest Oncology Group; E. David Crawford, University of Colorado Health Science Center; George Wilding, University of Wisconsin Hospital and Clinics; Atif Akdas, Marmara University Hospital in Istanbul, Turkey; Eric J. Small, University of California, San Francisco; Bryan Donnelly, Prostate Cancer Institute in Calgary, Canada; Gary MacVicar, Northwestern University; and Derek Raghavan, Cleveland Clinic Foundation.

Funding for the study was from the National Cancer Institute.

Reference: Journal of Clinical Oncology, Vol. 24, issue 24, pp. 3984-3990


Story Source:

The above story is based on materials provided by University of Michigan Health System. Note: Materials may be edited for content and length.


Cite This Page:

University of Michigan Health System. "PSA Predicts Treatment Success In Advanced Prostate Cancer." ScienceDaily. ScienceDaily, 24 August 2006. <www.sciencedaily.com/releases/2006/08/060823185000.htm>.
University of Michigan Health System. (2006, August 24). PSA Predicts Treatment Success In Advanced Prostate Cancer. ScienceDaily. Retrieved October 20, 2014 from www.sciencedaily.com/releases/2006/08/060823185000.htm
University of Michigan Health System. "PSA Predicts Treatment Success In Advanced Prostate Cancer." ScienceDaily. www.sciencedaily.com/releases/2006/08/060823185000.htm (accessed October 20, 2014).

Share This



More Health & Medicine News

Monday, October 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

How Nigeria Beat Its Ebola Outbreak

How Nigeria Beat Its Ebola Outbreak

Newsy (Oct. 20, 2014) The World Health Organization has declared Nigeria free of Ebola. Health experts credit a bit of luck and the government's initial response. Video provided by Newsy
Powered by NewsLook.com
Another Study Suggests Viagra Is Good For The Heart

Another Study Suggests Viagra Is Good For The Heart

Newsy (Oct. 20, 2014) An ingredient in erectile-dysfunction medications such as Viagra could improve heart function. Perhaps not surprising, given Viagra's history. Video provided by Newsy
Powered by NewsLook.com
Ebola Worries End for Dozens on U.S. Watch Lists

Ebola Worries End for Dozens on U.S. Watch Lists

Reuters - US Online Video (Oct. 20, 2014) Forty-three people who had contact with Thomas Eric Duncan, the first person diagnosed with Ebola in the U.S., were cleared overnight of twice-daily monitoring after 21 days of showing no symptoms. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
Beijing Marathon Runners Brave Hazardous Air Pollution

Beijing Marathon Runners Brave Hazardous Air Pollution

AFP (Oct. 19, 2014) Tens of thousands of runners battled thick smog at the Beijing Marathon on Sunday, with some donning masks as the levels of PM2.5 small pollutant particles soared to 16 times the maximum recommended level. Duration: 00:54 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins